In an era where real-world data (RWD) is rapidly transforming clinical research, one organization is harnessing this potential to shape the future of healthcare in Brazil and beyond. HCOR – Associação Beneficente Síria, a renowned healthcare institution based in São Paulo, has joined the TriNetX global network to amplify its impact on patient outcomes, medical innovation, and collaborative research.
A Strategic Move Toward Data-Driven Discovery
HCOR’s decision to join the TriNetX network was driven by a commitment to expand its capacity for real-world evidence (RWE) generation. According to Dr. Lucas Tramujas, the partnership directly supports HCOR’s mission: advancing patient care through clinical research, innovation, education, and global collaboration.
“By leveraging TriNetX’s powerful analytics and expansive data ecosystem, we’re able to bring even more scientific rigor and reach to our research,” said Dr. Tramujas. “It allows us to better translate clinical experience into actionable insights.”
Deep, High-Quality Clinical Data at the Core
As a contributor to the TriNetX LIVE™ platform, HCOR provides rich, detailed clinical data that spans several critical therapeutic areas. These include cardiology, internal medicine, oncology, and chronic diseases—areas in which HCOR has long-standing expertise. Their data contributions include diagnoses, procedures, medications, and laboratory results, offering a comprehensive view that bolsters the network’s overall utility for high-impact research.
“The depth of our data helps elevate the quality of the entire TriNetX network,” Dr. Tramujas emphasized. “It makes it possible for us and others to explore complex clinical questions with greater accuracy and confidence.”
Focusing on Cardiovascular Health and Beyond
HCOR’s research priorities are aligned with some of the most pressing health challenges of our time. Their primary interests within the TriNetX platform center around cardiovascular disease, metabolic disorders, oncology, and intensive care. Most recently, HCOR published two impactful studies on colchicine use, one in coronary artery disease and another in peripheral artery disease, demonstrating their commitment to applying TriNetX RWD to advance therapeutic insights.
Enabling Large-Scale, Multicenter Collaboration
TriNetX doesn’t just bring data: it brings connection. For HCOR, one of the most powerful aspects of the platform is the ability to collaborate more seamlessly with other healthcare institutions and pharmaceutical partners around the world.
“TriNetX gives us access to high-quality, de-identified patient data from multiple centers in real time,” said Dr. Tramujas. “This is key for designing and assessing the feasibility of multicenter studies, which are crucial for scalable and generalizable research outcomes.”
Driving Better Outcomes Through Innovation
Looking to the future, HCOR sees its partnership with TriNetX as a pivotal step toward advancing clinical care through innovation. By integrating RWD into its research and clinical workflows, HCOR aims to enhance evidence-based decision-making and accelerate the translation of insights into better outcomes for patients.
“We are committed to turning data into better care,” said Dr. Tramujas. “Our collaboration with TriNetX strengthens our ability to innovate, collaborate, and lead in delivering measurable improvements in patient health.”
HCOR’s partnership with TriNetX is more than a technological upgrade; it’s a bold step toward a smarter, more connected, and more patient-centered future in healthcare.
